About Mark
Mark Wicker provides strategic advice to companies and entrepreneurs to successfully exploit the latest technologies in a broad range of industries, including the life sciences, high technology, wireless, social media, clean technology, chemical, and materials sciences industries. Mr. Wicker has extensive experience developing innovative and effective business models, strategic alliances, partnerships, technology transactions and other business solutions for unique situations and problems. He specializes in structuring and negotiating creative and effective arrangements for the research, development, and commercialization of products and technologies, including joint ventures, corporate partnerships, licenses, contract research, and manufacturing and distribution alliances. In collaboration with our intellectual property litigation attorneys, he also structures effective adversarial licensing programs, and negotiates settlement and license agreements arising from patent and other intellectual property lawsuits. Additionally, he advises clients in venture capital financing, public securities offerings, mergers and acquisitions, and general corporate matters.Mr. Wicker has been instrumental in developing some of the most sophisticated business models and solutions for information technology, software, wireless, energy, materials sciences, chemical, agricultural, and life sciences transactions. He has advised Halozyme with its Enhanze technology collaboration program, Pure Bioscience with its SDC technology development and commercialization agreements, Biosite with its Biosite Discovery business unit, Sangamo with its zinc finger protein licensing strategy, Abgenix with its transgenic mouse platform, and Incyte Genomics in creating its early genomics business model. His solutions frequently draw from his wide and varied experience with different technologies, industries and transactions.Mr. Wicker is a frequent speaker on issues affecting the life sciences and technology industries, including industry trends, strategic alliances, technology development and commercialization, and capital raising. In addition, he regularly lectures on the formation and activities of start-up companies and on structuring, negotiating, and implementing collaborative and licensing transactions.While earning his J.D., Mr. Wicker was a Harlan Fiske Stone Scholar recipient, and a head writing and research editor for the Columbia Journal of Transnational Law.
Mark Wicker provides strategic advice to companies and entrepreneurs to successfully exploit the latest technologies in a broad range of industries, including the life sciences, high technology, wireless, social media, clean technology, chemical, and materials sciences industries. Mr. Wicker has extensive experience developing innovative and effective business models, strategic alliances, partnerships, technology transactions and other business solutions for unique situations and problems. He specializes in structuring and negotiating creative and effective arrangements for the research, development, and commercialization of products and technologies, including joint ventures, corporate partnerships, licenses, contract research, and manufacturing and distribution alliances. In collaboration with our intellectual property litigation attorneys, he also structures effective adversarial licensing programs, and negotiates settlement and license agreements arising from patent and other intellectual property lawsuits. Additionally, he advises clients in venture capital financing, public securities offerings, mergers and acquisitions, and general corporate matters.Mr. Wicker has been instrumental in developing some of the most sophisticated business models and solutions for information technology, software, wireless, energy, materials sciences, chemical, agricultural, and life sciences transactions. He has advised Halozyme with its Enhanze technology collaboration program, Pure Bioscience with its SDC technology development and commercialization agreements, Biosite with its Biosite Discovery business unit, Sangamo with its zinc finger protein licensing strategy, Abgenix with its transgenic mouse platform, and Incyte Genomics in creating its early genomics business model. His solutions frequently draw from his wide and varied experience with different technologies, industries and transactions.Mr. Wicker is a frequent speaker on issues affecting the life sciences and technology industries, including industry trends, strategic alliances, technology development and commercialization, and capital raising. In addition, he regularly lectures on the formation and activities of start-up companies and on structuring, negotiating, and implementing collaborative and licensing transactions.While earning his J.D., Mr. Wicker was a Harlan Fiske Stone Scholar recipient, and a head writing and research editor for the Columbia Journal of Transnational Law.
Mark Wicker provides strategic advice to companies and entrepreneurs to successfully exploit the latest technologies in a broad range of industries, including the life sciences, high technology, wireless, social media, clean technology, chemical, and materials sciences industries. Mr. Wicker has extensive experience developing innovative and effective business models, strategic alliances, partnerships, technology transactions and other business solutions for unique situations and problems. He specializes in structuring and negotiating creative and effective arrangements for the research, development, and commercialization of products and technologies, including joint ventures, corporate partnerships, licenses, contract research, and manufacturing and distribution alliances. In collaboration with our intellectual property litigation attorneys, he also structures effective adversarial licensing programs, and negotiates settlement and license agreements arising from patent and other intellectual property lawsuits. Additionally, he advises clients in venture capital financing, public securities offerings, mergers and acquisitions, and general corporate matters.
Mr. Wicker has been instrumental in developing some of the most sophisticated business models and solutions for information technology, software, wireless, energy, materials sciences, chemical, agricultural, and life sciences transactions. He has advised Halozyme with its Enhanze technology collaboration program, Pure Bioscience with its SDC technology development and commercialization agreements, Biosite with its Biosite Discovery business unit, Sangamo with its zinc finger protein licensing strategy, Abgenix with its transgenic mouse platform, and Incyte Genomics in creating its early genomics business model. His solutions frequently draw from his wide and varied experience with different technologies, industries and transactions.
Mr. Wicker is a frequent speaker on issues affecting the life sciences and technology industries, including industry trends, strategic alliances, technology development and commercialization, and capital raising. In addition, he regularly lectures on the formation and activities of start-up companies and on structuring, negotiating, and implementing collaborative and licensing transactions.
While earning his J.D., Mr. Wicker was a Harlan Fiske Stone Scholar recipient, and a head writing and research editor for the Columbia Journal of Transnational Law.
